“Ozempic lawsuit” usually refers to federal product-injury cases alleging gastrointestinal harm from Ozempic and other GLP-1 medicines. Those claims are being coordinated in one federal proceeding; separate vision-injury claims are in another. Neither proceeding, by itself, proves that a medicine caused a particular person’s injury or establishes that person’s eligibility to sue or recover money.
What the Ozempic gastrointestinal lawsuit is about
The main federal proceeding is MDL 3094 in the U.S. District Court for the Eastern District of Pennsylvania. An MDL, or multidistrict litigation, groups federal cases with shared factual questions before one judge for coordinated pretrial proceedings. The cases remain individual lawsuits; centralization is not a ruling on whether the claims are true.
The court describes claims involving alleged gastrointestinal injuries associated with GLP-1 receptor agonist medicines, including Ozempic. Plaintiffs raise shared questions about whether the manufacturers knew or should have known of alleged risks, whether warnings to patients and prescribers were adequate, and whether safety representations were misleading or incomplete. Novo Nordisk and Eli Lilly deny the allegations, according to the court’s MDL 3094 description.
Gastroparesis, sometimes called “stomach paralysis” in public discussion, is one of the conditions referenced in the litigation’s description. The case materials identify alleged gastroparesis and other gastrointestinal injuries as claims to be litigated—not as findings that Ozempic caused those conditions.
#1 Best Overall
Which medicines and companies are included?
The court’s MDL 3094 page names these medicines in the coordinated litigation:
| Manufacturer named by the court | Medicines named by the court |
|---|---|
| Novo Nordisk | Ozempic, Wegovy, Rybelsus |
| Eli Lilly | Trulicity, Mounjaro |
The proceeding concerns allegations involving the named GLP-1 medicines, not only Ozempic. The court says the Judicial Panel on Multidistrict Litigation centralized the cases for pretrial proceedings.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Are Ozempic vision-loss claims part of the same lawsuit?
No. Alleged vision injuries are being addressed in a separate federal proceeding, MDL 3163. The court describes that litigation as involving non-arteritic anterior ischemic optic neuropathy, or NAION, a specific type of optic-nerve injury, associated with GLP-1 medicines. Its page names Ozempic, Wegovy, and Saxenda among the Novo Nordisk products in scope. The NAION claims should not be conflated with the gastrointestinal allegations in MDL 3094.
| Federal proceeding | Alleged injury | Scope described by the court |
|---|---|---|
| MDL 3094 | Gastrointestinal injuries, including alleged gastroparesis | GLP-1 medicines named include Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro |
| MDL 3163 | NAION vision injuries | GLP-1 medicines named include Ozempic, Wegovy, and Saxenda |
What has the court decided, and what is the status?
The court’s case description identifies Judge Karen S. Marston and a Rule 702 evidentiary hearing scheduled for September 14–18, 2026, on cross-cutting issues 2 and 3 in MDL 3094. Rule 702 governs whether expert testimony is admissible. The MDL 3094 orders index lists an August 28, 2026 scheduling order for that hearing.
The cited court pages do not report the hearing’s outcome. They therefore do not establish whether expert testimony was admitted or excluded, what the court decided afterward, or whether later deadlines changed. A hearing notice is not a decision on the merits of the claims. For a procedural update after the hearing, consult the current MDL 3094 docket rather than relying on the schedule alone.
What the product label and FDA warning letter do—and do not—show
DailyMed identifies Ozempic as semaglutide injection and records a label update dated June 1, 2026. The label is the appropriate source for current prescribing and safety information; the court case descriptions do not substitute for medical advice or the live label.
Rank #4
The FDA issued Novo Nordisk a warning letter dated March 5, 2026, concerning postmarketing adverse-drug-experience reporting requirements. The letter discusses an inspection conducted January 13 through February 7, 2025, and cites reporting deficiencies. It is a regulatory communication about reporting duties—not a finding of liability in the private lawsuits, and not proof that Ozempic caused an individual injury.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Does being injured while taking Ozempic mean someone qualifies to sue?
Not on the information established by these court and regulatory materials. They describe the claims and shared issues in the proceedings; they do not decide an individual’s legal eligibility, whether a particular injury was caused by the medicine, or whether a person could obtain compensation. Those questions depend on individual facts and applicable law. Anyone considering a claim should seek advice from a qualified attorney rather than treating participation in an MDL or public allegations as a guarantee of recovery.
Recommended Free Tools
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
